AHA: Muvalaplin Reduces Lipoprotein(a) Levels in Individuals With Cardiovascular Risk
Reduction in levels seen using an intact lipoprotein(a) assay and apolipoprotein(a)-based assay
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.